Growth and growth hormone in children during and after therapy for acute lymphoblastic leukaemia

Eur J Pediatr. 1993 Sep;152(9):730-3. doi: 10.1007/BF01953986.

Abstract

Growth impairment and growth hormone (GH) deficiency have been reported in children treated for acute lymphoblastic leukaemia (ALL). We have studied growth and GH secretion in a group of 50 patients, affected by ALL, during a 2- to 5-year period after diagnosis, and in 12 "long-term-survivors". We observed a significant decrease in growth velocity during the 1st year (in particular during the first 6 months) of therapy and a catch-up growth after the end of therapy. "Long-term survivors" did not exhibit a significant reduction of height standard deviation score (SDS), as compared to height SDS at diagnosis. None of the patients showed GH deficiency. Our data indicate that chemotherapy significantly affects growth of patients treated for ALL, whereas radiotherapy-at the doses used in this study-does not induce GH deficiency, at least not within 9 years after diagnosis.

MeSH terms

  • Adolescent
  • Analysis of Variance
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Growth / drug effects*
  • Growth / radiation effects
  • Growth Disorders / chemically induced
  • Growth Hormone / metabolism*
  • Humans
  • Infant
  • Longitudinal Studies
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Radiotherapy / adverse effects

Substances

  • Growth Hormone